• Species Reactivity

  Human

• Specificity

  Detects human Matriptase/ST14 Catalytic Domain in direct ELISAs and Western blots.

• Source

  Monoclonal Mouse IgG1 Clone # 416802

• Immunogen

  E. coli-derived recombinant human Matriptase/ST14 Catalytic Domain    
  Val615-Val855    
  Accession # Q9Y5Y6

• Formulation

  Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide.

• Label

  Alexa Fluor 750

Applications

• Recommended    
  Concentration

  Sample

• Intracellular Staining by Flow Cytometry

  0.25-1 µg/10    ⁶ cells

  PC‑3 human prostate cancer cell line fixed with paraformaldehyde and permeabilized with saponin

• 
  

Please Note: Optimal dilutions should be determined by each laboratory for each application.  are available in the Technical Information section on our website.

Preparation and Storage

• Shipping

  The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

• Stability & Storage

  Store the unopened product at 2 - 8 °C. Do not use past expiration date.

Background: Matriptase/ST14

Human Matriptase, encoded by the ST14 (suppression of tumorogenicity 14) gene, is also known as tumor associated differentially expressed gene 15 protein/TADG‑15), epithin, and membrane-type serine protease 1/MT-SP1 (1). Predicted to have a significant role in tumor biology, Matriptase may be a novel target for anti-cancer therapy (2). However, expressed in most human epithelia, Matriptase is also important in several physiological processes (1). For example, it activates prostasin to initiate a protease cascade that is essential for epidermal differentiation (3), and it converts a single-chain IGFBP-rp1 into the two-chain form (4). Matriptase is a type II transmembrane serine protease with a complex modular structure (1). The 855 amino acid (aa) sequence of human Matriptase consists of a cytoplasmic tail (aa 1‑55), a transmembrane domain (aa 56‑76), and an extracellular portion (aa 77‑855). The latter contains the following domains: SEA (aa 86‑201), two CUBs (aa 214‑334 and 340‑447), four LDLRAs (aa 452‑486, 487‑523, 524‑560, and 566‑603), and a serine protease (aa 615‑855). The physiological activation of the single-chain zymogen requires the cleavage at the SEA domain within the ER or Golgi, association with HAI-1, which facilitates the transport of the protease to the cell surface, and auto-cleavage at QAR-V(615)VGG (1). The activated Matriptase is inhibited by HAI-1, and the resulting HAI-1 complex can be shed from the cell surface (1).

• References:

1. List, K. et al. (2006) Mol. Med. 12:1.

2. Uhland, K. (2006) Cell. Mol. Life Sci. 63:2968.

3. Netzel-Arnett, S. et al. (2006) J. Biol. Chem. 281:32941.

4. Ahmed, S. et al. (2006) FEBS J. 273:615.

• Entrez Gene IDs:

  6768 (Human); 19143 (Mouse); 114093 (Rat)

• Alternate Names:

  EC 3.4.21; Epithin; HAI; Matriptase; Membrane-type serine protease 1; MTSP1; MT-SP1EC 3.4.21.109; prostamin; PRSS14; Serine protease 14; Serine protease TADG-15; SNC19; SNC19MTSP1; ST14; suppression of tumorigenicity 14 (colon carcinoma); suppression of tumorigenicity 14 (colon carcinoma, matriptase, epithin); suppressor of tumorigenicity 14 protein; TADG15; TADG-15; TMPRSS14; tumor associated differentially expressed gene 15 protein; Tumor-associated differentially-expressed gene 15 protein